Company Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester.
IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 124 |
| CEO | Yujiro S. Hata |
Contact Details
Address: 7000 Shoreline Court, Suite 350 South San Francisco, California 94080 United States | |
| Phone | 650-443-6209 |
| Website | ideayabio.com |
Stock Details
| Ticker Symbol | IDYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001676725 |
| CUSIP Number | 45166A102 |
| ISIN Number | US45166A1025 |
| Employer ID | 47-4268251 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yujiro S. Hata | President, Chief Executive Officer and Director |
| Dr. Michael A. White Ph.D. | Chief Scientific Officer |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer |
| Andres Ruiz Briseno CPA | Principal Accounting Officer, Senior Vice President and Head of Finance and Investor Relations |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer |
| Jason S. Throne Esq., J.D. | Chief Legal Officer and Company Secretary |
| Mick O'Quigley | Chief of Staff and Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 20, 2024 | 10-K | Annual Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |